Comparative P solubilizing efficiencies of five acid soil bacteria incubated with calcium, aluminium and iron phosphates

As acid soils of Odisha have been facing a major constraint in phosphorus availability, application of native P solubilizing bacteria could be promising as well as ecofriendly step towards sustainable P availability for crop growth and development. To address the problem of P availability in acid soil of Bhubaneswar, Odisha, rhizosphere soil samples (pH ? 5.50) with rice – pulses (green gram/black gram) cropping system were collected and phosphate solubilising bacteria were isolated. In vitro characterization of the PSB isolates were conducted with calcium, aluminium and iron phosphates to recover soluble P. All the five strains i.e. Bacillus cereus BLS18 (KT582541), Bacillus amyloliquefaciens CTC12 (KT633845), Burkholderia cepacia KHD08 (KT717633), Burkholderia cepacia KJR03 (KT717634), Burkholderia cepacia K1 (KM030037) could solubilize Ca3(PO4)2, AlPO4, FePO4, and Fe3(PO4)2. Higher recovery of soluble P was with Ca3(PO4)2 while the least was with AlPO4. All the strains exibited a trend similar with respect to P recovery i.e. Ca3(PO4)2 > FePO4 > AlPO4 > Fe3(PO4)2. B. amyloliquefaciens CTC12 was most efficient in solubilizing calcium and iron phosphates whereas B. cepacia KHD08 recovered maximum P with aluminium phosphate. All the inorganic salt fortified mediums showed a significant decline in pH which necessitated the identification of compounds present in the mediums. Organic acids viz; acetic, citric, gluconic, lactic, malic, succinic, tartaric acids in the mediums were identified by HPLC. Tartaric acid was only found in the mediums supplemented with AlPO4. B. amyloliquefaciens CTC12 and B. cepacia KHD08 showed promising results in in vitro analysis of P solubilization. The present study is focused on problematic acid soils where phosphorous is unavailable and mostly fixed with aluminium and iron ultimately making it unavailable for the crops to take up. This leads to unbalanced and frequent use of chemical fertilizer. Hence the study is a significant attempt to characterize native PSBs with capacity to solubilize Al-P and Fe-P

Effect of low dose aspirin on maternal outcome in women at risk for developing pregnancy induced hypertension

Background: Pre-eclampsia is not totally a preventable disease. It is found more related to chains of social ills such as poor maternal nutrition, limited or no antenatal care and poor reproductive education. However, some specific “high-risk” factors leading to pregnancy induced hypertension (PIH) may be identified in individuals which include and not limited to young and elderly primigravida, multiple pregnancy, diabetes, Rh incompatibility, new paternity, pre-existing vascular or renal disease, family history of hypertension, pre-eclampsia and eclampsia, obesity, thrombophilia. Low dose aspirin given in 2nd trimester in these high-risk women is anticipated to prevent the development of PIH.Methods: This prospective randomized controlled trial was conducted in the department of obstetrics and gynecology, SCB MC and Hospital, Cuttack during November 2018 to October 2019. Pregnant women between the gestational age of 13th to 28th weeks were screened for risk factors and included in this study. Low dose aspirin of 60 mg daily till delivery was given to pregnant women who consented to be a part of study randomly with the other group having placebo.Results: Protienuric hypertension was high in control group who did not receive aspirin. Low dose aspirin significantly reduces PIH in high-risk group (3.48% in case versus 23.52% in control). Low dose aspirin was not associated with significant increase in placental bleeding. Low dose aspirin was generally safe for the fetus and new born infant with no evidence of an increased likelihood of bleeding.Conclusions: Low dose aspirin has a definite role in the prevention of PIH in high risk pregnancy. Low dose aspirin reduces the incidence of PIH. Low dose aspirin can be considered a safe drug without any deleterious side effect for mother and the fetus. Benefits of prevention of PIH, justifies its administration in women at high risk.

Effect of low dose aspirin on fetal outcome in women at risk for developing pregnancy induced hypertension

Background: Though pregnancy induced hypertension is a worldwide problem, it is more prevalent in developing countries particularly south east Asian and African countries. It contributes to 20% of perinatal death and 40-50% of low birth weight babies in India. Fetal salvage is also an important consideration in providing quality care. Low dose aspirin given between 12 weeks to 28 weeks of gestational age in high-risk women at Developing Pregnancy Induced Hypertension (PIH) is anticipated to prevent the development of PIH and complications that arises especially those regarding maternal and fetal mortality due to PIH.Methods: This prospective randomized controlled trial was conducted in the dept of O and G, SCB MC and Hospital, Cuttack during November 2018 to October 2019. Pregnant women between the gestational age of 13 to 28 week were screened for risk factors and included in this study. Low dose aspirin of 60 mg daily till delivery was given to pregnant women who consented to be a part of study randomly with the other group taking placebo.Results: Incidence of IUGR babies in low dose aspirin treated mothers was as low as 1%. Incidence of LBW babies is lower in low dose aspirin treated mothers than with those who were not treated. Mean birth weight in cases was 2780 gm'352 gm vs control 2592 gm'483 gm. There is increased incidence of still birth in high risk group not treated with aspirin. No significant difference in reducing incidence premature deliveries between case and control.Conclusions: Low dose aspirin has a definite role in the prevention of PIH in high risk pregnancy and its complication like IUGR and low birth weight. Low dose aspirin reduces the incidence of PIH. Low dose aspirin can be considered a safe drug without any deleterious side effect for mother and the fetus. Benefits of prevention of PIH, justifies its administration in women at high risk.